Karlsgodt KH, Sun D, Cannon TD. Structural and Functional Brain Abnormalities in Schizophrenia. Curr Dir Psychol Sci. 2010;19:226–31.

Article  PubMed  PubMed Central  Google Scholar 

Evans JD, Heaton RK, Paulsen JS, McAdams LA, Heaton SC, Jeste DV. Schizoaffective disorder: a form of schizophrenia or affective disorder? J Clin Psychiatry. 1999;60:874–82.

Article  CAS  PubMed  Google Scholar 

Harvey PD, Heaton RK, Carpenter WT Jr., Green MF, Gold JM, Schoenbaum M. Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res. 2012;140:1–8.

Article  PubMed  PubMed Central  Google Scholar 

Cotton SM, Lambert M, Schimmelmann BG, Mackinnon A, Gleeson JFM, Berk M, Hides L, Chanen AM, Scott J, Schottle D, McGorry PD, Conus P. Differences between first episode schizophrenia and schizoaffective disorder. Schizophr Res. 2013;147:169–74.

Article  CAS  PubMed  Google Scholar 

Amann BL, Canales-Rodriguez EJ, Madre M, Radua J, Monte G, Alonso-Lana S, Landin-Romero R, Moreno-Alcazar A, Bonnin CM, Sarro S, Ortiz-Gil J, Gomar JJ, Moro N, Fernandez-Corcuera P, Goikolea JM, Blanch J, Salvador R, Vieta E, McKenna PJ, Pomarol-Clotet E. Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2016;133:23–33.

Article  CAS  PubMed  Google Scholar 

Ivleva EI, Bidesi AS, Keshavan MS, Pearlson GD, Meda SA, Dodig D, Moates AF, Lu H, Francis AN, Tandon N, Schretlen DJ, Sweeney JA, Clementz BA, Tamminga CA. Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry. 2013;170:1285–96.

Article  PubMed  PubMed Central  Google Scholar 

Walther S, Lefebvre S, Conring F, Gangl N, Nadesalingam N, Alexaki D, Wuthrich F, Ruter M, Viher PV, Federspiel A, Wiest R, Stegmayer K. Limbic links to paranoia: increased resting-state functional connectivity between amygdala, hippocampus and orbitofrontal cortex in schizophrenia patients with paranoia. Eur Arch Psychiatry Clin Neurosci. 2022;272:1021–32.

Article  PubMed  Google Scholar 

Nawaz R, Gul S, Amin R, Huma T, Al Mughairbi F. Overview of schizophrenia research and treatment in Pakistan. Heliyon. 2020;6:e5545.

Article  PubMed  PubMed Central  Google Scholar 

Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, McGrath JJ, Whiteford HA. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study. Schizophr Bull. 2016;2018(44):1195–203.

Google Scholar 

Wildgust HJ, Hodgson R, Beary M. The paradox of premature mortality in schizophrenia: new research questions. J Psychopharmacol. 2010;24:9–15.

Article  PubMed  PubMed Central  Google Scholar 

Wildgust HJ, Beary M. Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? J Psychopharmacol. 2010;24:37–50.

Article  PubMed  PubMed Central  Google Scholar 

van Mierlo HC, Schot A, Boks MPM, de Witte LD. The association between schizophrenia and the immune system: Review of the evidence from unbiased ‘omic-studies. Schizophr Res. 2020;217:114–23.

Article  PubMed  Google Scholar 

Dietert RR. Role of developmental immunotoxicity and immune dysfunction in chronic disease and cancer. Reprod Toxicol. 2011;31:319–26.

Article  CAS  PubMed  Google Scholar 

Ezeoke A, Mellor A, Buckley P, Miller B. A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr Res. 2013;150:245–51.

Article  PubMed  Google Scholar 

Tiosano S, Farhi A, Watad A, Grysman N, Stryjer R, Amital H, Comaneshter D, Cohen AD, Amital D. Schizophrenia among patients with systemic lupus erythematosus: population-based cross-sectional study. Epidemiol Psychiatr Sci. 2017;26:424–9.

Article  CAS  PubMed  Google Scholar 

Oken RJ, Schulzer M. At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr Bull. 1999;25:625–38.

Article  CAS  PubMed  Google Scholar 

Juvonen H, Reunanen A, Haukka J, Muhonen M, Suvisaari J, Arajarvi R, Partonen T, Lonnqvist J. Incidence of schizophrenia in a nationwide cohort of patients with type 1 diabetes mellitus. Arch Gen Psychiatry. 2007;64:894–9.

Article  PubMed  Google Scholar 

Cullen AE, Holmes S, Pollak TA, Blackman G, Joyce DW, Kempton MJ, Murray RM, McGuire P, Mondelli V. Associations Between Non-neurological Autoimmune Disorders and Psychosis: A Meta-analysis. Biol Psychiatry. 2019;85:35–48.

Article  PubMed  PubMed Central  Google Scholar 

Eaton WW, Hayward C, Ram R. Schizophrenia and rheumatoid arthritis: a review. Schizophr Res. 1992;6:181–92.

Article  CAS  PubMed  Google Scholar 

Vinogradov S, Gottesman MHW II, Nicol S. Negative association between schizophrenia and rheumatoid arthritis. Schizophr Bull. 1991;17:669–78.

Article  CAS  PubMed  Google Scholar 

Bending D, Zaccone P, Cooke A. Inflammation and type one diabetes. Int Immunol. 2012;24:339–46.

Article  CAS  PubMed  Google Scholar 

Streisand R, Monaghan M. Young children with type 1 diabetes: challenges, research, and future directions. Curr Diab Rep. 2014;14:520.

Article  PubMed  PubMed Central  Google Scholar 

Whittemore R, Jaser S, Chao A, Jang M, Grey M. Psychological experience of parents of children with type 1 diabetes: a systematic mixed-studies review. Diabetes Educ. 2012;38:562–79.

Article  PubMed  PubMed Central  Google Scholar 

Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034–54.

Article  PubMed  PubMed Central  Google Scholar 

Bryden KS, Dunger DB, Mayou RA, Peveler RC, Neil HA. Poor prognosis of young adults with type 1 diabetes: a longitudinal study. Diabetes Care. 2003;26:1052–7.

Article  PubMed  Google Scholar 

Delamater AM, Jacobson AM, Anderson B, Cox D, Fisher L, Lustman P, Rubin R, Wysocki T. Psychosocial therapies in diabetes: report of the Psychosocial Therapies Working Group. Diabetes Care. 2001;24:1286–92.

Article  CAS  PubMed  Google Scholar 

Vaseghi H, Jadali Z. Th1/Th2 cytokines in Type 1 diabetes: Relation to duration of disease and gender. Indian J Endocrinol Metab. 2016;20:312–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Avgustin B, Wraber B, Tavcar R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J. 2005;46:268–74.

PubMed  Google Scholar 

Na KS, Kim YK. Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology. 2007;56:55–63.

Article  CAS  PubMed  Google Scholar 

Shao S, He F, Yang Y, Yuan G, Zhang M, Yu X. Th17 cells in type 1 diabetes. Cell Immunol. 2012;280:16–21.

Article  CAS  PubMed  Google Scholar 

Debnath M, Berk M. Th17 pathway-mediated immunopathogenesis of schizophrenia: mechanisms and implications. Schizophr Bull. 2014;40:1412–21.

Article  PubMed  PubMed Central  Google Scholar 

Subbanna M, Shivakumar V, Bhalerao G, Varambally S, Venkatasubramanian G, Debnath M. Variants of Th17 pathway-related genes influence brain morphometric changes and the risk of schizophrenia through epistatic interactions. Psychiatr Genet. 2022;32:146–55.

Article  CAS  PubMed  Google Scholar 

Arif S, Moore F, Marks K, Bouckenooghe T, Dayan CM, Planas R, Vives-Pi M, Powrie J, Tree T, Marchetti P, Huang GC, Gurzov EN, Pujol-Borrell R, Eizirik DL, Peakman M. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes. 2011;60:2112–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol. 2009;39:216–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pugliese A. Insulitis in the pathogenesis of type 1 diabetes. Pediatr Diabetes. 2016;17(Suppl 22):31–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietilainen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Borglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Bottcher Y, Olesen J, Breuer R, Moller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Rethelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA, Genetic R, Outcome in P, Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jonsson EG, Terenius L, Agartz I, Petursson H, Nothen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA. Common variants conferring risk of schizophrenia. Nature. 2009;460:744–747.

Stringer S, Kahn RS, de Witte LD, Ophoff RA, Derks EM. Genetic liability for schizophrenia predicts risk of immune disorders. Schizophr Res. 2014;159:347–52.